DeepMed Research

China National Biotec Group Company Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated

Phase 4

Active, not recruiting

Conditions: Covid19

Interventions: Biological: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Biological: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Biological: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Biological: 2 doses of vaccine

First Posted Date: 2021-04-28

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 4400

Registration Number: NCT04863638

Locations: 🇨🇳
Yanjin County Center for Disease Control and Prevention, Xinxiang, Henan, China

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

Phase 4

Completed

Conditions: Pneumonia, Pneumococcal
Covid19
Influenza, Human

Interventions: Biological: IIV4 for the 1st dose and PPV23 for the 2nd dose
Biological: COVAX only (1st and 2nd dose)
Biological: COVAX+IIV4; COVAX+PPV23

First Posted Date: 2021-03-10

Last Posted Date: 2021-10-20

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1133

Registration Number: NCT04790851

Locations: 🇨🇳
Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China
🇨🇳
Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
🇨🇳
Sichuan Center for Disease Control and Prevention, Chengdu, China

A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old

Phase 4

Completed

Conditions: Vaccination

Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine

First Posted Date: 2021-01-08

Last Posted Date: 2022-02-16

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 330

Registration Number: NCT04700618

Locations: 🇨🇳
Shanghai municipal center for disease control and prevention, Shanghai, Shanghai, China

A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly

Phase 4

Completed

Conditions: Vaccination

Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine

First Posted Date: 2021-01-08

Last Posted Date: 2022-02-16

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 331

Registration Number: NCT04701788

Locations: 🇨🇳
Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China

Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR

Phase 4

Conditions: Vaccine

Interventions: Biological: sIPV
Biological: sIPV+DTaP+MMR
Biological: DTaP
Biological: MMR

First Posted Date: 2020-11-20

Last Posted Date: 2020-12-10

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 600

Registration Number: NCT04638985

Locations: 🇨🇳
Anhui Provincial Center for Disease Control and Prevention, Hefei, Anhui, China
🇨🇳
Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China
🇨🇳
Jiangsu Province Centers for Disease Control and Prevention, Nanjing, Jiangsu, China

Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA

Phase 4

Conditions: Vaccination

Interventions: Biological: sIPV
Biological: DTaP
Biological: sIPV+DTaP+HepA
Biological: HepA

First Posted Date: 2020-11-19

Last Posted Date: 2020-11-19

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 600

Registration Number: NCT04636827

Locations: 🇨🇳
Hebei Provincial Center for Disease Control and Prevention, Shijia Zhuang, Hebei, China
🇨🇳
Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, Shaanxi, China
🇨🇳
Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, Shanxi, China

Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine

Phase 4

Conditions: Vaccination

Interventions: Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun
Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang
Biological: Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS

First Posted Date: 2020-11-03

Last Posted Date: 2021-02-26

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 450

Registration Number: NCT04612634

Locations: 🇨🇳
Mianxian Center for Disease Control and Prevention, Hanzhong, Shaanxi, China
🇨🇳
Yangxian Center for Disease Control and Prevention, Hanzhong, Shaanxi, China

Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

Phase 4

Completed

Conditions: Influenza, Human
Pneumonia, Pneumococcal

Interventions: Biological: IIV4 and PPV23
Biological: IIV4
Biological: PPV23

First Posted Date: 2020-09-22

Last Posted Date: 2022-08-02

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1224

Registration Number: NCT04559204

Locations: 🇨🇳
Luodong County Health Center, Quanzhou, Fujian, China
🇨🇳
Qidong County Center for Disease Control and Prevention, Qidong, Hunan, China
🇨🇳
Liucheng Community Health Services Center, Quanzhou, Fujian, China

and more 1 locations

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Biological: Placebo

First Posted Date: 2020-08-12

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 44101

Registration Number: NCT04510207

Locations: 🇯🇴
Prince Hamza Hospital, Amman, Jordan
🇦🇪
Al Qarain Primary Health Care Centre-MOHAP, Sharjah, United Arab Emirates
🇪🇬
Vacsera health Care facilities , MoH, Cairo, Egypt

and more 3 locations

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Phase 4

Completed

Conditions: Influenza
Enterovirus Infections

Interventions: Biological: EV71 vaccine
Biological: influenza vaccine
Biological: EV71 vaccine and influenza vaccine

First Posted Date: 2019-09-17

Last Posted Date: 2022-10-12

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1134

Registration Number: NCT04091880

Locations: 🇨🇳
Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy